<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00618020</url>
  </required_header>
  <id_info>
    <org_study_id>4C-b No. OVC-C01</org_study_id>
    <nct_id>NCT00618020</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the CiTop™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries</brief_title>
  <official_title>A Feasibility Study to Evaluate the Safety and Efficacy of the CiTop™ Guidewire for Crossing Chronic Total Occlusion in Coronary Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ovalum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ovalum</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CiTop™ guidewire Coronary study is a feasibility open label study, to evaluate the safety
      and efficacy of the CiTop™ Guidewire for crossing chronic total occlusion in Coronary
      arteries.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic documentation of placement of CiTop™ distal to occlusion with no device related major complications.</measure>
    <time_frame>during procedure, 1day, 1week and 30 days post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful stenting</measure>
    <time_frame>During procedure, Day1, Day7 and Day30 post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wire crossing duration</measure>
    <time_frame>during procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>during procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of contrast</measure>
    <time_frame>during procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maneuverability of the CiTop™ up to the occlusion</measure>
    <time_frame>during procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No mechanical damage to the device during</measure>
    <time_frame>during procedure</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Coronary Occlusion</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CiTop(tm) Guidewire</intervention_name>
    <description>CiTop(tm)6 Guidewire</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent obtained prior to any trial activities.

          2. Patients, male or female between 21 and 80 years of age, with no significant
             co-morbidities (see exclusion criteria).

          3. Patient has an angiographic documented Chronic Total Occlusion showing distal TIMI
             flow 0 to 1.

        Exclusion Criteria:

          1. Patient unable to give informed consent.

          2. Current participation in another study with any investigational drug or device.

          3. Factors making follow-up and/or repeat angiography difficult or unlikely.

          4. Contra-indication to emergency artery by pass surgery.

          5. Lack of surgical backup.

          6. Contra-indication to treatment with Aspirin, or Clopidogrel and/or Heparin.

          7. Lesion &gt; 40mm in length (both calcified lesion and adjacent thrombus).

          8. Treated vessel referenced diameter less than 2.5 mm.

          9. Visualization of the distal lumen less than the Rentrop Classification Grade 2
             collateralization.

         10. Non-visible entry point of target lesion.

         11. Totally occluded bypass graft as target vessel.

         12. Acute MI less than 1 week before procedure.

         13. Patient has significant LV dysfunction, 35% LVEF or less.

         14. Patient with cancer or other sever chronic disease with life expectance of 2 years.

         15. Patient has chronic renal failure with serum creatinine ≥2.

         16. Hemoglobin ≤11.

         17. Patient is known or suspected not to tolerate the contrast agent.

         18. Morbid Obesity (BMI &gt; 40).

         19. Drug abuse or alcoholism.

         20. Patients under custodial care.

         21. Pregnant women or women with childbearing potential with a positive pregnancy test at
             the time of procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keyur Parikh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chairman,CardioVascular Services,SAL Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>S.A.L Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2008</study_first_submitted>
  <study_first_submitted_qc>February 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2008</study_first_posted>
  <last_update_submitted>July 17, 2008</last_update_submitted>
  <last_update_submitted_qc>July 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Clinical Affairs</name_title>
    <organization>Ovalum Ltd.</organization>
  </responsible_party>
  <keyword>CTO</keyword>
  <keyword>Chronic Total Occlusion</keyword>
  <keyword>Revascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Occlusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

